{"id":784,"date":"2026-06-27T02:50:35","date_gmt":"2026-06-27T06:50:35","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/inside-klow-blend-four-component-breakdown"},"modified":"2026-11-09T08:35:51","modified_gmt":"2026-11-09T13:35:51","slug":"inside-klow-blend-four-component-breakdown","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/inside-klow-blend-four-component-breakdown","title":{"rendered":"Inside the KLOW Blend: What BPC-157, GHK-Cu, TB-500, and KPV Each Contribute to the Four-Component Formulation"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-177\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg.png\" alt=\"KLOW Blend components BPC-157 GHK-Cu TB-500 KPV four-peptide skin recovery research Durham Peptides Canada\" width=\"1122\" height=\"1402\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg.png 1122w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg-240x300.webp 240w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg-819x1024.webp 819w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg-768x960.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/klow-80mg-800x1000.webp 800w\" sizes=\"(max-width: 1122px) 100vw, 1122px\" \/><\/figure>\n<p>KLOW Blend components BPC-157 GHK-Cu TB-500 KPV four-peptide skin research Durham Peptides Canada<\/p>\n<p>The KLOW Blend is Durham Peptides' most ambitious multi-component formulation \u2014 four distinct peptides engineered into a single co-lyophilized vial, addressing four different mechanisms in parallel for skin and connective-tissue research. Most coverage of KLOW treats it as the \"GLOW + KPV\" four-component combination, which is technically accurate but misses the more useful question: <strong>what does each of the four components actually contribute to the combination's research profile?<\/strong> This article opens the hood per-component, modeled on the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/inside-glow-blend-three-component-breakdown\/\" target=\"_blank\">Inside the GLOW Blend<\/a><\/u> approach.<\/p>\n<p>For the standalone KLOW Blend overview, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-klow-blend\/\" target=\"_blank\">What Is the KLOW Blend?<\/a><\/u>; for the GLOW vs KLOW comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u>; for the broader blend decision framework, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/when-to-use-peptide-blend\/\" target=\"_blank\">When Do You Actually Need a Peptide Blend?<\/a><\/u>. Nothing here is medical, dosing, or therapeutic guidance.<\/p>\n<p><strong>The Composition<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/klow-blend-bpc-157-ghk-cu-tb-500-kpv-80mg\/\" target=\"_blank\">KLOW Blend<\/a><\/u> at Durham Peptides:<\/p>\n<ul><li><strong>10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500 + 10mg KPV = 80mg total per vial<\/strong><\/li><li><strong>1:5:1:1 component ratio<\/strong> (GHK-Cu dominant by mass)<\/li><li>Single co-lyophilized vial<\/li><li><strong>C$169.96 per vial<\/strong> (C$2.12 per total milligram of peptide)<\/li><li>\u226599% purity per component, Janoshik-verified with mass-spec identity for each peptide independently<\/li><\/ul>\n<p>The four-component design extends the three-component GLOW Blend by adding KPV as a fourth peptide \u2014 bringing in a dedicated inflammatory-signaling mechanism alongside the three GLOW mechanisms (gene expression, angiogenesis, cell migration).<\/p>\n<p><strong>Component 1: GHK-Cu \u2014 The Gene Expression and Collagen Anchor (50mg)<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ghk-cu\/\" target=\"_blank\">GHK-Cu<\/a><\/u> is the dominant component by mass and the most-studied peptide in the formulation. The copper tripeptide has over 100 published research studies spanning decades.<\/p>\n<p><strong>What GHK-Cu contributes to KLOW:<\/strong><\/p>\n<ul><li><strong>Gene expression modulation<\/strong> across hundreds of genes including collagen genes, inflammatory mediators, and antioxidant response genes<\/li><li><strong>Collagen synthesis stimulation<\/strong> \u2014 primarily Type I and Type III collagen, the structural proteins of skin and connective tissue<\/li><li><strong>Wound-model research<\/strong> \u2014 the foundational research application for copper peptides<\/li><li><strong>Inflammatory-signaling effects<\/strong> through TNF-\u03b1, IL-6, and NF-\u03baB pathway modulation<\/li><li><strong>Copper-peptide chemistry effects<\/strong> \u2014 copper is mechanistically essential, not decorative; copper-dependent enzymes (lysyl oxidase, SOD) contribute to the broader research mechanism<\/li><\/ul>\n<p><strong>Why 50mg specifically:<\/strong> GHK-Cu research typically uses higher milligram quantities than the other components, reflecting how the underlying skin and connective tissue research has historically been designed.<\/p>\n<p>For the GHK-Cu deep-dive, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/copper-peptides-explained\/\" target=\"_blank\">Copper Peptides Explained<\/a><\/u>; for the hair-specific extension, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/ghk-cu-for-hair-research\/\" target=\"_blank\">GHK-Cu for Hair Research<\/a><\/u>.<\/p>\n<p><strong>Component 2: BPC-157 \u2014 The Angiogenesis Mechanism (10mg)<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bpc-157\/\" target=\"_blank\">BPC-157<\/a><\/u> \u2014 Body Protection Compound 157 \u2014 is the 15-amino-acid gastric-juice-derived pentadecapeptide.<\/p>\n<p><strong>What BPC-157 contributes to KLOW:<\/strong><\/p>\n<ul><li><strong>Angiogenesis<\/strong> \u2014 investigated effects on new blood vessel formation through VEGFR2 and nitric oxide signaling. New blood vessels deliver oxygen, nutrients, and cells to the area being supported.<\/li><li><strong>Vascular and tissue protection<\/strong> \u2014 beyond angiogenesis, BPC-157 has been studied for vascular integrity effects.<\/li><li><strong>Broad tissue research relevance<\/strong> \u2014 although originally identified in gastric research, BPC-157's literature extends through multiple tissue types relevant to skin, tissue and connective tissue research.<\/li><\/ul>\n<p><strong>Why 10mg specifically:<\/strong> Standard single-vial research quantity for BPC-157, well-aligned with typical research consumption rates and matched 1:1 with TB-500 (echoing the Wolverine Stack proportions). For the broader BPC-157 context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-bpc-157\/\" target=\"_blank\">What Is BPC-157?<\/a><\/u> et <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/bpc-157-brain-gut-axis-research\/\" target=\"_blank\">BPC-157 for Brain-Gut Axis Research<\/a><\/u>.<\/p>\n<p><strong>Component 3: TB-500 \u2014 The Cell Migration Mechanism (10mg)<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/tb-500-10mg\/\" target=\"_blank\">TB-500<\/a><\/u> is the synthetic fragment of Thymosin Beta-4, the 44-amino-acid actin-regulating peptide.<\/p>\n<p><strong>What TB-500 contributes to KLOW:<\/strong><\/p>\n<ul><li><strong>Cell migration<\/strong> \u2014 investigated effects on actin regulation and the physical movement of cells (fibroblasts, endothelial cells, immune cells) toward target sites<\/li><li><strong>Connective tissue research relevance<\/strong> \u2014 TB-500 has substantial published research in tendon and ligament biology where cell migration is a recognized bottleneck<\/li><li><strong>Vascular endothelial cell migration<\/strong> \u2014 overlapping with the BPC-157 angiogenesis thread through the cell-migration angle<\/li><li><strong>Cardiac research thread<\/strong> \u2014 extending the actin biology to cardiac research contexts<\/li><\/ul>\n<p><strong>Why 10mg specifically:<\/strong> Matched 1:1 with BPC-157, paralleling the Wolverine Stack 1:1 ratio. The pairing of these two tissue-research peptides at equal proportions is the established standard.<\/p>\n<p><strong>Component 4: KPV \u2014 The Inflammatory-Signaling Mechanism (10mg)<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/kpv-10mg\/\" target=\"_blank\">KPV<\/a><\/u> is the three-amino-acid C-terminal fragment of \u03b1-MSH (alpha-melanocyte-stimulating hormone), and the \"K\" in KLOW.<\/p>\n<p><strong>What KPV contributes to KLOW (the component that differentiates KLOW from GLOW):<\/strong><\/p>\n<ul><li><strong>\u03b1-MSH-derived inflammatory signaling<\/strong> \u2014 KPV retains the inflammatory-signaling portion of \u03b1-MSH biology while being structurally simple<\/li><li><strong>NF-\u03baB pathway modulation<\/strong> \u2014 relevant to multiple inflammatory contexts including skin, gut, and broader tissue research<\/li><li><strong>Pro-inflammatory cytokine signaling<\/strong> \u2014 investigated effects on TNF-\u03b1, IL-6, and IL-1\u03b2 in research models<\/li><li><strong>Skin-research relevance<\/strong> \u2014 \u03b1-MSH is one of the major peptide hormones in skin biology; see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/kpv-for-skin-research\/\" target=\"_blank\">KPV for Skin Research<\/a><\/u><\/li><li><strong>PepT1-mediated intestinal uptake<\/strong> \u2014 particularly relevant for IBD research; see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/kpv-inflammatory-bowel-disease-research\/\" target=\"_blank\">KPV for Inflammatory Bowel Disease Research<\/a><\/u><\/li><\/ul>\n<p><strong>Why 10mg specifically:<\/strong> Matched to the BPC-157 and TB-500 quantities, reflecting KPV's typical research-consumption rates.<\/p>\n<p><strong>Why Four Mechanisms Work Together<\/strong><\/p>\n<p>This is the core research-design point of the KLOW Blend: the four components engage <\/p>\n<p><strong>four genuinely complementary mechanisms<\/strong> that address different aspects of skin, tissue and tissue research without redundantly hitting the same pathway.<\/p>\n<table><tr><td><p>Component<\/p><\/td><td><p>Primary Mechanism<\/p><\/td><td><p>What It Addresses<\/p><\/td><\/tr><tr><td><p><strong>GHK-Cu<\/strong><\/p><\/td><td><p>Gene expression, collagen synthesis<\/p><\/td><td><p>The \"what to build\" \u2014 gene programs and matrix proteins<\/p><\/td><\/tr><tr><td><p><strong>BPC-157<\/strong><\/p><\/td><td><p>Angiogenesis<\/p><\/td><td><p>The \"blood supply\" \u2014 new vessels delivering oxygen, nutrients, cells<\/p><\/td><\/tr><tr><td><p><strong>TB-500<\/strong><\/p><\/td><td><p>Cell migration<\/p><\/td><td><p>The \"cell mobilization\" \u2014 cells physically arriving at the site<\/p><\/td><\/tr><tr><td><p><strong>KPV<\/strong><\/p><\/td><td><p>Inflammatory signaling<\/p><\/td><td><p>The \"inflammatory signaling\" \u2014 modulating the inflammatory environment<\/p><\/td><\/tr><\/table>\n<p>This is the conceptual scaffold the KLOW Blend extends from GLOW. GLOW provides three of the four mechanisms (the building, the blood supply, the cell delivery). KLOW adds the fourth \u2014 explicit inflammatory-signaling mechanism \u2014 for research designs where inflammation modulation is part of the picture.<\/p>\n<p>The fourth mechanism matters because <strong>inflammation is part of repair biology, not separate from it.<\/strong> Productive repair requires a controlled inflammatory phase that resolves at the right time; chronic or dysregulated inflammation impairs the other three mechanisms. Adding KPV's inflammatory-signaling mechanism alongside the GLOW components addresses the inflammation-modulation question explicitly.<\/p>\n<p>For the related per-component breakdown, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/inside-glow-blend-three-component-breakdown\/\" target=\"_blank\">Inside the GLOW Blend<\/a><\/u>.<\/p>\n<p><strong>KLOW vs GLOW: When the Fourth Component Matters<\/strong><\/p>\n<p>The choice between <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/klow-blend-bpc-157-ghk-cu-tb-500-kpv-80mg\/\" target=\"_blank\">KLOW<\/a><\/u> et <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/glow-blend-ghk-cu-50-mg-bpc-157-10-mg-tb-500-10-mg-70mg\/\" target=\"_blank\">GLOW<\/a><\/u> comes down to whether your research design specifically needs the dedicated inflammatory-signaling mechanism:<\/p>\n<ul><li><strong>Choose KLOW when<\/strong>: Research involves inflammatory contexts (skin inflammation, broader inflammatory-signaling questions, gut research where the PepT1 angle matters), or when the four-mechanism scope matches your research question<\/li><li><strong>Choose GLOW when<\/strong>: Research focuses on the three core mechanisms (gene expression, angiogenesis, cell migration) without specific inflammatory-signaling questions, and the slightly lower cost is preferable<\/li><\/ul>\n<p>For the detailed comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u>; for the broader Wolverine-vs-GLOW comparison (no-GHK-Cu vs three-component), see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/wolverine-stack-vs-glow-blend\/\" target=\"_blank\">Wolverine Stack vs Glow Blend<\/a><\/u>.<\/p>\n<p><strong>The Component-Level Pricing Math<\/strong><\/p>\n<p>KLOW Blend per-component equivalent at separate vial quantities:<\/p>\n<ul><li>10mg BPC-157 alone: C$65.69<\/li><li>50mg GHK-Cu alone: C$54.99<\/li><li>10mg TB-500 alone: C$79.69<\/li><li>10mg KPV alone: C$45.99<\/li><li><strong>Combined equivalent: ~C$246.36<\/strong> vs KLOW Blend at C$169.96<\/li><\/ul>\n<p>The blend saves approximately <strong>C$76 per equivalent quantity<\/strong> compared to buying the four components separately at standalone vial quantities \u2014 about 31% savings, plus the documentation, reconstitution, and ratio-consistency benefits of a single co-formulated product.<\/p>\n<p>For the cost-comparison framework, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/wolverine-stack-vs-glow-blend\/\" target=\"_blank\">Wolverine Stack vs Glow Blend<\/a><\/u> (which works through similar per-component math).<\/p>\n<p><strong>Practical Research Considerations<\/strong><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/klow-blend-bpc-157-ghk-cu-tb-500-kpv-80mg\/\" target=\"_blank\">KLOW Blend 80mg<\/a><\/u> at Durham Peptides is C$169.96. Janoshik-verified per component (four separate HPLC and mass-spec identity confirmations on the one batch), \u226599% purity per peptide, 100% synthetic, vegan. Storage: 2\u20138\u00b0C short-term, -20\u00b0C long-term, protected from light and moisture; reconstitute in <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bacteriostatic-water-10ml\/\" target=\"_blank\">eau bact\u00e9riostatique<\/a><\/u>.<\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><strong>What does the KLOW Blend contain?<\/strong> Four peptides co-lyophilized: 10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500 + 10mg KPV = 80mg total per vial. Each component is Janoshik-verified independently.<\/p>\n<p><strong>What's the difference between KLOW and GLOW?<\/strong> KLOW = GLOW + KPV. GLOW is three peptides (GHK-Cu + BPC-157 + TB-500); KLOW adds KPV as a fourth dedicated inflammatory-signaling component. See <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u>.<\/p>\n<p><strong>Why is the GHK-Cu component 50mg when the others are 10mg?<\/strong> Because GHK-Cu research typically uses higher milligram quantities than the other components \u2014 reflecting the typical relative quantities in the published research literature for these compounds.<\/p>\n<p><strong>Does KLOW save money compared to buying the components separately?<\/strong> Yes \u2014 approximately 31% savings (C$76 per equivalent quantity) versus buying the four components at standalone vial quantities. Plus documentation, reconstitution, and ratio-consistency benefits.<\/p>\n<p><strong>Is KLOW better than GLOW?<\/strong> Neither is universally better \u2014 they answer different research questions. KLOW is better when research design specifically engages inflammatory-signaling mechanisms alongside the GLOW three-component approach. GLOW is sufficient when the three core mechanisms cover the research question.<\/p>\n<p><strong>Where can I buy the KLOW Blend in Canada?<\/strong> Durham Peptides supplies the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/klow-blend-bpc-157-ghk-cu-tb-500-kpv-80mg\/\" target=\"_blank\">KLOW Blend 80mg<\/a><\/u> (C$169.96) \u2014 Janoshik-verified per component, \u226599% purity, 100% synthetic.<\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p>The KLOW Blend's four-component design represents Durham Peptides' most ambitious multi-mechanism research formulation \u2014 engaging gene expression and collagen synthesis (GHK-Cu), angiogenesis (BPC-157), cell migration (TB-500), and inflammatory signaling (KPV) in a single co-lyophilized vial at established research proportions. The fourth component (KPV) extends the three-mechanism GLOW Blend by adding dedicated inflammatory signaling \u2014 addressing inflammation modulation as an explicit fourth dimension of skin, tissue and tissue research rather than leaving it as an implicit consequence of the other mechanisms. For research designed around the multi-mechanism approach with inflammatory-signaling questions specifically engaged, KLOW is the standardized way to access all four mechanisms at the proportions the published research has established.<\/p>\n<p>For the standalone overview, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-klow-blend\/\" target=\"_blank\">What Is the KLOW Blend?<\/a><\/u>; for the per-component breakdown of the three-component sibling, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/inside-glow-blend-three-component-breakdown\/\" target=\"_blank\">Inside the GLOW Blend<\/a><\/u>; for the direct GLOW vs KLOW comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/glow-vs-klow\/\" target=\"_blank\">GLOW vs KLOW<\/a><\/u>; for the Wolverine alternative, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/wolverine-stack-vs-glow-blend\/\" target=\"_blank\">Wolverine Stack vs Glow Blend<\/a><\/u>.<\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<ol><li>Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. <em>International Journal of Molecular Sciences<\/em>. 2018;19(7):1987. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29986520\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29986520\/<\/a><\/u><\/li><li>Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. <em>Current Pharmaceutical Design<\/em>. 2011;17(16):1612-1632. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21548867\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/21548867\/<\/a><\/u><\/li><li>Goldstein AL, Hannappel E, Kleinman HK. Thymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues. <em>Trends in Molecular Medicine<\/em>. 2005;11(9):421-429. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16099219\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16099219\/<\/a><\/u><\/li><li>Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. <em>Gastroenterology<\/em>. 2008;134(1):166-178. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18061177\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/18061177\/<\/a><\/u><\/li><\/ol>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"KLOW Blend components BPC-157 GHK-Cu TB-500 KPV four-peptide skin research Durham Peptides Canada The KLOW Blend is Durham Peptides' most ambitious multi-component formulation \u2014 four distinct peptides engineered into a single co-lyophilized vial, addressing four different mechanisms in parallel for skin and connective-tissue research. Most coverage of KLOW treats it as the \"GLOW + KPV\" four-component combination, which is technically accurate but misses the more useful question:...","protected":false},"author":1,"featured_media":177,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-784","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=784"}],"version-history":[{"count":2,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/784\/revisions"}],"predecessor-version":[{"id":2678,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/784\/revisions\/2678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/177"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}